BTK
Los inhibidores de la tirosina quinasa de Bruton (BTK) son compuestos que específicamente se dirigen e inhiben la BTK, una enzima crucial involucrada en la señalización del receptor de células B y en la regulación de la angiogénesis. La BTK desempeña un papel significativo en la proliferación y supervivencia de las células cancerosas, particularmente en las malignidades hematológicas. Al inhibir la BTK, estos compuestos pueden interrumpir la angiogénesis y el crecimiento tumoral, lo que los convierte en valiosos en la terapia contra el cáncer. En CymitQuimica, ofrecemos una gama de inhibidores de BTK de alta calidad para apoyar su investigación en oncología, inmunología y angiogénesis.
Se han encontrado 162 productos de "BTK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
BTK-IN-23
CAS:BTK-IN-23: BTK inhibitor, IC50=12.8 nM; also blocks BLX (35.6 nM), BMX (5.7 nM); better selectivity than Ibrutinib.Fórmula:C27H28N6O2Forma y color:SolidPeso molecular:468.55BTK-IN-22
CAS:BTK-IN-22 is a selective BTK inhibitor with IC50 of 0.9 nM; also targets BLX, BMX (IC50s: 1.4, 1.2 nM); better selectivity than Ibrutinib.Fórmula:C26H26N6O2Forma y color:SolidPeso molecular:454.52Ibrutinib-MPEA
CAS:Ibrutinib-MPEA is ibrutinib derivative. Ibrutinib is a covalent and irreversible BTK inhibitor that has been used to treat hematological malignancies.Fórmula:C32H39N9O2Forma y color:SolidPeso molecular:581.71HZ-A-005
CAS:HZ-A-005 is a selective, potent, covalent inhibitor of Bruton's tyrosine kinase (BTK). HZ-A-005 significantly inhibits tumour growth in a xenograft mouse model.Fórmula:C25H23ClN6O2Forma y color:SolidPeso molecular:474.94GDC-0834 S-enantiomer
CAS:GDC-0834, the S-enantiomer, is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK).Fórmula:C33H36N6O3SPureza:98%Forma y color:SolidPeso molecular:596.74BLK-IN-2
CAS:<p>BLK-IN-2为一种高效、选择性且不可逆的B-淋巴酪氨酸激酶(BLK)抑制剂，具有5.9 nM的IC50值。该化合物亦能抑制BTK，其IC50值为202.0 nM。BLK-IN-2在多种淋巴瘤细胞中展现出显著的抗增殖作用。</p>Fórmula:C39H41N9O3Forma y color:SolidPeso molecular:683.8Spebrutinib besylate
CAS:Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).Fórmula:C28H28FN5O6SPureza:98%Forma y color:SolidPeso molecular:581.62JNJ-64264681
CAS:JNJ-64264681 is a potent, orally active, selective, and irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK).Fórmula:C27H30N6O3SPureza:98%Forma y color:SolidPeso molecular:518.63DPPY
CAS:DPPY inhibits EGFR, BTK, JAK3 (IC50<10 nM), curbs B-cell lymphoma growth, and may be studied for IPF treatment.Fórmula:C25H26ClN7O3Forma y color:SolidPeso molecular:507.97GDC-0834 Racemate
CAS:GDC-0834 Racemate is the racemate form of GDC-0834, which is an effective and selective BTK inhibitorFórmula:C33H36N6O3SForma y color:SolidPeso molecular:596.74NX-2127
CAS:NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferativeFórmula:C39H45N9O5Pureza:99.07%Forma y color:SolidPeso molecular:719.83Tilfrinib
CAS:Tilfrinib is an effective and selective inhibitor of breast tumor kinase(Brk, IC50 = 3.15 nM) which displays anti-proliferative and anti-tumor activities.Fórmula:C17H13N3OPureza:99.54%Forma y color:SolidPeso molecular:275.3CHMFL-EGFR-202
CAS:CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).Fórmula:C25H24ClN7O2Pureza:99.66%Forma y color:SolidPeso molecular:489.96(±)-Zanubrutinib
CAS:(±)-Zanubrutinib ((±)-BGB-3111) is a potent and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability,Fórmula:C27H29N5O3Pureza:99.09%Forma y color:SolidPeso molecular:471.55Sunvozertinib
CAS:Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2.Cost-effective and quality-assured.Fórmula:C29H35ClFN7O3Pureza:98.11% - 99.63%Forma y color:SolidPeso molecular:584.08Larotinib
CAS:Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.Fórmula:C24H26ClFN4O4Pureza:99.73%Forma y color:SolidPeso molecular:488.94(R)-Zanubrutinib
CAS:(R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).Fórmula:C27H29N5O3Pureza:99.55%Forma y color:SolidPeso molecular:471.55PF-303
CAS:PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.Fórmula:C22H21ClN6O2Forma y color:SolidPeso molecular:436.89BTK inhibitor 20
CAS:BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .Fórmula:C37H42N8O4Forma y color:SolidPeso molecular:662.78BTK-IN-19
CAS:BTK-IN-19 is a reversible BTK inhibitor with an IC 50 of <0.001 μM .Fórmula:C21H22Cl2N6OForma y color:SolidPeso molecular:445.35(Rac)-PF-06250112
CAS:(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.Fórmula:C22H20F2N6O2Pureza:98%Forma y color:SolidPeso molecular:438.43BTK-IN-18
CAS:BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.Fórmula:C20H22Cl2N6OForma y color:SolidPeso molecular:433.33BTK-IN-17
BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.Fórmula:C26H23N7O2Forma y color:SolidPeso molecular:465.51BTK-IN-11
CAS:BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)Fórmula:C26H22ClN5O3Forma y color:SolidPeso molecular:487.94DDa-1
CAS:DDa-1 is a potent (kinase degrader) [1].Fórmula:C60H77Cl2N13O3SForma y color:SoildPeso molecular:1131.31BTK inhibitor 13
CAS:BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM).Fórmula:C29H26FN5O3Pureza:98%Forma y color:SolidPeso molecular:511.55Pirtobrutinib
CAS:Pirtobrutinib: a selective, non-covalent BTK inhibitor effective against BTK C481 mutations, causing tumor regression in lymphoma models.Fórmula:C22H21F4N5O3Pureza:99.76% - 99.94%Forma y color:SolidPeso molecular:479.43Cinsebrutinib
CAS:Cinsebrutinib, a Bruton's tyrosine kinase inhibitor, holds potential for research in cancer treatment.Fórmula:C22H26FN3O2Pureza:98%Forma y color:SolidPeso molecular:383.46Edralbrutinib
CAS:Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity and is used in the treatment of tumors, immune system disorders, and blood andFórmula:C26H21F2N5O3Pureza:99.41%Forma y color:SolidPeso molecular:489.47BMX-IN-1
CAS:BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosineFórmula:C29H24N4O4SPureza:98.38%Forma y color:SolidPeso molecular:524.59PF-06250112
CAS:PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM.Fórmula:C22H20F2N6O2Pureza:98%Forma y color:SolidPeso molecular:438.43BTK inhibitor 1
CAS:<p>BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM.</p>Fórmula:C24H23FN8O2Pureza:98.24% - 98.91%Forma y color:SolidPeso molecular:474.49BMS-935177
CAS:BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.Fórmula:C31H26N4O3Pureza:99.89%Forma y color:SolidPeso molecular:502.56TAK-020
CAS:TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.Fórmula:C18H17N5O3Pureza:98.66%Forma y color:SolidPeso molecular:351.36BMS-986143
CAS:BMS-986143: oral BTK inhibitor, IC50=0.26 nM, potential for autoimmune research, also targets TEC, BLK, BMX, TXK, YES1, ITK.Fórmula:C31H24Cl2N4O4Forma y color:SolidPeso molecular:587.45JAK3/BTK-IN-3
CAS:JAK3/BTK-IN-3: strong dual JAK3/BTK suppressor, promising for autoimmune disease research.Fórmula:C22H28N8OForma y color:SolidPeso molecular:420.51JAK3/BTK-IN-4
CAS:JAK3/BTK-IN-4, a dual inhibitor for JAK3/BTK, shows synergy in autoimmune disease treatment. (Patent WO2021147953A1, compound 003)Fórmula:C21H25ClN8OForma y color:SolidPeso molecular:440.93BTK-IN-32
CAS:BTK-IN-32 (compound C2) acts as a potent BTK inhibitor. Unlike isolated kinase domains, this compound activates full-length BTK as well as its smaller multidomain fragments [1].Fórmula:C35H35ClN4O3SPeso molecular:627.2BTK-IN-10
CAS:BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).Fórmula:C25H24F2N4O2Forma y color:SolidPeso molecular:450.48(Rac)-Ibrutinib alkyne
CAS:(Rac)-Ibrutinib alkyne (Compound 8) is a Btk inhibitor with an IC50 of 0.72 nM. This compound effectively inhibits B cell receptor signaling functions, with an IC50 of 9 nM for calcium flux inhibition in Ramos cells. (Rac)-Ibrutinib alkyne is applicable in research on diseases such as rheumatoid arthritis.Fórmula:C25H22N6O2Forma y color:SolidPeso molecular:438.48BTK-IN-15
BTK-IN-15: Oral BTK inhibitor, IC50 0.7 nM, induces cancer cell apoptosis, selective with anti-tumor effects.Fórmula:C28H24FN5O2Forma y color:SolidPeso molecular:481.52BTK inhibitor 18
BTK inhibitor 18 is a selective, potent, covalent, orally active Btk inhibitor (IC50: 142 nM) that exhibits anti-inflammatory effects.Fórmula:C29H25N5O4S2Forma y color:SolidPeso molecular:571.67BTK-IN-6
BTK-IN-6, a potent BTK inhibitor, may treat immune, cardiac, cancer, viral, inflammatory, metabolic, and neurological disorders.Fórmula:C23H22FN5O3Forma y color:SolidPeso molecular:435.45RET-IN-14
CAS:RET-IN-14 inhibits RET (IC50: <0.51-9.3 nM) & BTK (C481S) (IC50: 9.2-15 nM), promising for tumor research.Fórmula:C24H23FN8O4Forma y color:SolidPeso molecular:506.49BIIB129
CAS:BIIB129 is a selective and brain-penetrant BTK covalent inhibitor used to study B-cell proliferation-related diseases.Fórmula:C19H22N6O2Pureza:98.56%Forma y color:SolidPeso molecular:366.42WS-11
CAS:WS-11 is a non-covalent reversible inhibitor of BTK, with IC50 values of 3.9 nM for the wild-type and 2.2 nM for the C481S mutant BTK. In addition to strong hydrogen bonding, WS-11 also forms robust π-π interactions with PHE540, and p-π interactions with LYS430 within the active pocket.Fórmula:C26H22FN9O2Forma y color:SolidPeso molecular:511.51BTK-IN-38
CAS:BTK-IN-38 (Example 125) is an efficacious inhibitor of BTK. It effectively suppresses the proliferation of DOHH2 and BT474 cells, with IC50 values of 114 nM and 340 nM, respectively.Fórmula:C27H26F2N4O2Forma y color:SolidPeso molecular:476.52BTK-IN-16
CAS:BTK-IN-16 is a potential inhibitor of wild-type BTK and C481S mutants.BTK-IN-16 can be used to study various autoimmune diseases and cancers caused by BTK.Fórmula:C15H14N4O2Pureza:99.04%Forma y color:SoildPeso molecular:282.3G-744
CAS:G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM).Fórmula:C29H29N5O3SPureza:98%Forma y color:SolidPeso molecular:527.64TQ-3959
CAS:TQ-3959 is an orally active BTKPROTAC degrader, with a DC50 of 14.6 nM. It exhibits antiproliferative activity against both wild-type BTK and BTK C481S mutant cell lines. TQ-3959 demonstrates tumor growth inhibition in female NOD-SCID mice with TMD-8 xenografts. This compound is applicable in the study of B-cell malignancies, such as lymphoma.Fórmula:C40H47N11O5Forma y color:SolidPeso molecular:761.87UBX-382
CAS:UBX-382 is an orally administered proteolysis-targeting chimera (PROTAC) designed to target BTK and disrupt B-cell receptor signaling. It demonstrates enhanced degradation of both wild-type and mutant BTK proteins, exhibiting anti-cancer effects in murine xenograft models using TMD-8 cells [1].Fórmula:C42H44N10O4Peso molecular:752.86BTK-IN-34
CAS:BTK-IN-34 (compound 9h) functions as a selective BTK inhibitor, exhibiting antiproliferative effects in RAMOS cells by specifically targeting pBTK (Tyr223) while sparing upstream proteins such as Lyn and Syk in the BCR signaling pathway [1].Fórmula:C22H29N3O4SPeso molecular:431.55HDHD4-IN-1
CAS:HDHD4-IN-1 (compound 3) is an inhibitor of N-acetylneuraminate-9-phosphate phosphatase (HDHD4) with an IC50 value of 11 μM. It is utilized in the research of neurological disorders.Fórmula:C12H22NO11PForma y color:SolidPeso molecular:387.28GNE-431
CAS:GNE-431: potent, selective noncovalent Btk inhibitor, IC50=3.2 nM; effective against C481R, T474I, T474M mutants, may counter ibrutinib resistance.Fórmula:C30H32N10O2Forma y color:SolidPeso molecular:564.64JAK3/BTK-IN-7
CAS:JAK3/BTK-IN-7 (XL-12), characterized as a JAK3/BTK inhibitor, exhibits IC 50 values of 2 nM and 14 nM for JAK3 and BTK respectively. This compound demonstrates anti-inflammatory properties and is applicable in research related to rheumatoid arthritis [1].Fórmula:C29H30N8O4Forma y color:SolidPeso molecular:554.6BTK-IN-8
BTK-IN-8: potent, selective covalent BTK inhibitor; IC50=0.22 nM, Kd=0.91 nM; effective in blood CD69 cells (IC50=0.029 μM).Fórmula:C26H36N6O3Forma y color:SolidPeso molecular:480.6Brefeldin A 4-O-nicotinate
CAS:Brefeldin A 4-O-nicotinate (CHNQD-01228) is a dual inhibitor of Arf1 and BMX proteins with an IC50 value of 0.22 μM for T24 cell proliferation. It also suppresses T24 cell migration and colony formation in a dose-dependent manner, induces G1 phase arrest, and triggers apoptosis. By targeting BMX proteins, it inhibits the AKT/p-AKT and STAT3/p-STAT3 signaling pathways, while also inhibiting Arf1 proteins to eliminate bladder cancer stem cells and activate antitumor immunity, thus exhibiting anticancer activity. Brefeldin A 4-O-nicotinate is applicable in research related to bladder cancer.Fórmula:C22H27NO5Forma y color:SolidPeso molecular:385.453Ibrutinib Racemate
CAS:Ibrutinib is a selective, irreversible Btk inhibitor (IC50: 0.5 nM). Ibrutinib Racemate is the racemate of Ibrutinib.Fórmula:C25H24N6O2Pureza:98%Forma y color:SolidPeso molecular:440.5Dihydrodiol-Ibrutinib
CAS:PCI 45227 is an active metabolite of the Bruton's tyrosine kinase inhibitor ibrutinib .1PCI 45227 is formed from ibrutinib by the cytochrome P450 (CYP) isoform CYP3A. 1.Veeraraghavan, S., Viswanadha, S., Thappali, S., et al.Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic studyJ. Pharm. Biomed. Anal.107151-158(2015)Fórmula:C25H26N6O4Forma y color:SolidPeso molecular:474.521BTK-IN-25
CAS:<p>BTK-IN-25 (compound 71) is a potent BTK inhibitor, demonstrating an IC50 of 0.77 nM against BTK(C481S) and achieving an IC50 of 1 nM in DOHH2 cells [1].</p>Fórmula:C28H27F2N3O5Pureza:98%Forma y color:SolidPeso molecular:523.53JDB175
CAS:<p>JDB175, a selective BTK inhibitor with oral bioavailability, demonstrates excellent penetration through the blood-brain barrier.</p>Fórmula:C26H21F3N4O2Pureza:98%Forma y color:SolidPeso molecular:478.47BTK-IN-27
CAS:<p>BTK-IN-27 (example 8), a potent BTK inhibitor with an IC50 of 0.2 nM, demonstrates anti-proliferative effects in TMD8 cells with an IC50 of less than 5 nM.</p>Fórmula:C31H35N7O2Pureza:98%Forma y color:SolidPeso molecular:537.66
